SEOUL, South Korea--(BUSINESS WIRE)--GICELL announced research and development collaboration for allogeneic CAR-NK candidates with HK inno.N on August 29th, 2022.
HK inno.N, buoyed by its $500 million IPO, has teamed up with Ilias Biologics to co-develop candidates using exosomes. The partnership brings together Ilias’ exosome platform technologies and HK inno.N’s drug development chops.
Indian firm Dr. Reddy’s Laboratories has entered into an exclusive partnership with South Korea-based HK inno.N Corporation, for the supply and commercialisation of HK inno.N Corporation’s patented novel molecule Tegoprazan for gastrointestinal diseases in India and six key Emerging Markets.
Dr. Reddy’s Laboratories to commercialise novel molecule Tegoprazan in India
inno.N's gastroesophageal reflux disease (GERD) therapy, K-CAB, has become a blockbuster drug by surpassing annual sales of 100 billion won ($83.8 million) in just three years of its launch, the fastest among homegrown treatments.